General
Preferred name
TRELAGLIPTIN
Synonyms
SYR-472 ()
SYR-472 succinate ()
SYR472 ()
TRELAGLIPTIN SUCCINATE ()
Trelagliptin (succinate) ()
Trelagliptina ()
Trelagliptine ()
SYR-111472 Succinate ()
SYR111472 SUCCINATE ()
Zafatek ()
Trelagliptin-13C-d3 ()
TRELAGLIPTINA ()
TRELAGLIPTINE ()
P&D ID
PD012587
CAS
1029877-94-8
865759-25-7
2707203-34-5
Tags
available
drug
Approved by
PMDA
First approval
2015
Drug indication
Metabolic disorder
type 2 diabetes mellitus
Non-insulin dependent diabetes
diabetes mellitus
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM)[1].
PRICE
51
DESCRIPTION
Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM)[1].
PRICE
31
DESCRIPTION
Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with trelagliptin in Japan to evaluate its safety and efficacy in a once-weekly oral treatment regimen. Currently, all available DPP-4 inhibitors are dosed once-daily. A once-weekly treatment, such as trelagliptin, would provide patients with a convenient treatment alternative and has the potential to improve treatment compliance.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Trelagliptin (SYR-472) is a highly specific, long-acting DPP-4 inhibitor.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Trelagliptin succinate (SYR-472 succinate) is a long-acting inhibitor of dipeptidyl peptidase-4 (DPP-4), being developed for the treatment of type 2 diabetes (T2D).
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
17
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
EUbOPEN Chemogenomics Library
LSP-MoA library (Laboratory of Systems Pharmacology)
ReFrame library
Selleckchem Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
43
Molecular Weight
357.16
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
3
Ring Count
3
Aromatic Ring Count
2
cLogP
0.53
TPSA
97.05
Fraction CSP3
0.39
Chiral centers
1.0
Largest ring
6.0
QED
0.86
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Dipeptidyl Peptidase
DPP-4
DPP4
DPP4 inhibitor
DPP
Indication
diabetes mellitus
MOA
dipeptidyl peptidase inhibitor
Pathway
Proteases/Proteasome
Ubiquitination
Metabolic Enzyme/Protease
Recommended Cell Concentration
None
Source data
